<DOC>
	<DOC>NCT01825551</DOC>
	<brief_summary>The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.</brief_summary>
	<brief_title>The Effect of GCSF in the Treatment of ALS Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>age between 18 and 85 definite or probable ALS according to revised El Escorial criteria maximum 2 years from initiation of symptoms to study entry mild to moderate disability according to revised ALS functional rating scale (ALSFRSr) familial ALS pregnancy or lactation myeloproliferative or hematologic disorders active immunological disease liver or renal or heart disease HIV positive significant cognitive disorder hypersensitivity to GCSF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Granulocyte Colony Stimulating Factor</keyword>
</DOC>